159 related articles for article (PubMed ID: 20049927)
1. Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group.
Bensimhon P; Villablanca JG; Sender LS; Matthay KK; Park JR; Seeger R; London WB; Yap JS; Kreissman SG
Pediatr Blood Cancer; 2010 Apr; 54(4):596-602. PubMed ID: 20049927
[TBL] [Abstract][Full Text] [Related]
2. A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support.
Pradhan KR; Johnson CS; Vik TA; Sender LS; Kreissman SG
Pediatr Blood Cancer; 2006 Jun; 46(7):793-802. PubMed ID: 16206215
[TBL] [Abstract][Full Text] [Related]
3. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
[TBL] [Abstract][Full Text] [Related]
4. Pilot Study of Intensive Chemotherapy With Peripheral Hematopoietic Cell Support for Children Less Than 3 Years of Age With Malignant Brain Tumors, the CCG-99703 Phase I/II Study. A Report From the Children's Oncology Group.
Cohen BH; Geyer JR; Miller DC; Curran JG; Zhou T; Holmes E; Ingles SA; Dunkel IJ; Hilden J; Packer RJ; Pollack IF; Gajjar A; Finlay JL;
Pediatr Neurol; 2015 Jul; 53(1):31-46. PubMed ID: 26092413
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human granulocyte colony-stimulating factor infusion and/or autologous peripheral blood stem cell transplantation as a rescue for sequential high-dose combination chemotherapy: a preliminary report.
Chau WK; Lin CK; Chow MP; Wang SY; Liu JM; Ho CH; Chiu CF; Hsu HC; Tan TD; Chan WK
Zhonghua Yi Xue Za Zhi (Taipei); 1994 Nov; 54(5):312-20. PubMed ID: 7530591
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group.
Zage PE; Kletzel M; Murray K; Marcus R; Castleberry R; Zhang Y; London WB; Kretschmar C;
Pediatr Blood Cancer; 2008 Dec; 51(6):747-53. PubMed ID: 18704922
[TBL] [Abstract][Full Text] [Related]
7. Multidisciplinary therapy including high-dose chemotherapy followed by peripheral blood stem cell transplantation for invasive thymoma.
Iwasaki Y; Ohsugi S; Takemura Y; Nagata K; Harada H; Nakagawa M
Chest; 2002 Dec; 122(6):2249-52. PubMed ID: 12475873
[TBL] [Abstract][Full Text] [Related]
8. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
[TBL] [Abstract][Full Text] [Related]
9. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.
Kreissman SG; Seeger RC; Matthay KK; London WB; Sposto R; Grupp SA; Haas-Kogan DA; Laquaglia MP; Yu AL; Diller L; Buxton A; Park JR; Cohn SL; Maris JM; Reynolds CP; Villablanca JG
Lancet Oncol; 2013 Sep; 14(10):999-1008. PubMed ID: 23890779
[TBL] [Abstract][Full Text] [Related]
10. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.
Kaneko M; Tsuchida Y; Mugishima H; Ohnuma N; Yamamoto K; Kawa K; Iwafuchi M; Sawada T; Suita S
J Pediatr Hematol Oncol; 2002 Nov; 24(8):613-21. PubMed ID: 12439032
[TBL] [Abstract][Full Text] [Related]
11. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM
Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
[TBL] [Abstract][Full Text] [Related]
12. A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer.
Takahashi M; Yoshizawa H; Tanaka H; Tanaka J; Kagamu H; Ito K; Shimbo T; Chou D; Wakabayashi M; Suzuki E; Sakai K; Arakawa M; Gejyo F
Bone Marrow Transplant; 2000 Jan; 25(1):5-11. PubMed ID: 10654007
[TBL] [Abstract][Full Text] [Related]
13. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
[TBL] [Abstract][Full Text] [Related]
14. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.
Kushner BH; LaQuaglia MP; Bonilla MA; Lindsley K; Rosenfield N; Yeh S; Eddy J; Gerald WL; Heller G; Cheung NK
J Clin Oncol; 1994 Dec; 12(12):2607-13. PubMed ID: 7527454
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of efficacy of treatment for 30 children with neuroblastoma].
Sun XF; Liu DG; Su YS; Lin TY; Chen XQ; He YJ
Ai Zheng; 2003 Dec; 22(12):1343-5. PubMed ID: 14693065
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature.
Kushner BH; Modak S; Kramer K; Basu EM; Roberts SS; Cheung NK
Cancer; 2013 Feb; 119(3):665-71. PubMed ID: 22951749
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
Matthay KK; Tan JC; Villablanca JG; Yanik GA; Veatch J; Franc B; Twomey E; Horn B; Reynolds CP; Groshen S; Seeger RC; Maris JM
J Clin Oncol; 2006 Jan; 24(3):500-6. PubMed ID: 16421427
[TBL] [Abstract][Full Text] [Related]
18. Results of a prospective clinical trial JN-L-10 using image-defined risk factors to inform surgical decisions for children with low-risk neuroblastoma disease: A report from the Japan Children's Cancer Group Neuroblastoma Committee.
Iehara T; Yoneda A; Yokota I; Takahashi H; Teramukai S; Kamijyo T; Nakazawa A; Takimoto T; Kikuta A; Yagyu S; Ikeda H; Nakagawara A; Tajiri T;
Pediatr Blood Cancer; 2019 Nov; 66(11):e27914. PubMed ID: 31342649
[TBL] [Abstract][Full Text] [Related]
19. RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma.
Thomson B; Hawkins D; Felgenhauer J; Radich J
Bone Marrow Transplant; 1999 Sep; 24(5):527-33. PubMed ID: 10482938
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells.
Schilder RJ; Johnson S; Gallo J; Kindsfather S; Rogers B; Bookman MA; Millenson MM; Boente M; Rosenblum N; Litwin S; Ozols RF
J Clin Oncol; 1999 Jul; 17(7):2198-207. PubMed ID: 10561276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]